Why the study?
Does nadolol reduce the frequency of ambulatory ischemic episodes in patients with stable coronary artery disease?
Population
20 patients with stable coronary artery disease
Comparison
Nadolol administered for a 2-week treatment phase vs Matching placebo administered for a 2-week…
Design
RCT, randomized crossover, double-blind, placebo-controlled
Follow-up
2 weeks per treatment phase
Authors
Loading...
Supports nadolol for fewer ambulatory ischemic episodes in stable CAD; confirms efficacy against activity-driven triggers.
Does nadolol reduce the frequency of ambulatory ischemic episodes in patients with stable coronary artery disease?
The morning increase in ambulatory ischemia is driven by physical activity and heart rate increases, which are effectively reduced by nadolol, although nadolol may paradoxically increase ischemic episodes not driven by heart rate.
Parker et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: